0.3241
price down icon2.56%   -0.0085
after-market 시간 외 거래: .32 -0.0041 -1.27%
loading
전일 마감가:
$0.3326
열려 있는:
$0.3326
하루 거래량:
755.10K
Relative Volume:
0.34
시가총액:
$18.02M
수익:
$30.99M
순이익/손실:
$-141.41M
주가수익비율:
-2.1607
EPS:
-0.15
순현금흐름:
$-118.12M
1주 성능:
+11.76%
1개월 성능:
-81.79%
6개월 성능:
-78.54%
1년 성능:
-95.36%
1일 변동 폭
Value
$0.3177
$0.3326
1주일 범위
Value
$0.2875
$0.3458
52주 변동 폭
Value
$0.2603
$11.26

Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile

Name
명칭
Marinus Pharmaceuticals Inc
Name
전화
484-801-4670
Name
주소
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Name
직원
166
Name
트위터
@MarinusPharma
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
MRNS's Discussions on Twitter

Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-01-20 개시 RBC Capital Mkts Outperform
2020-09-30 개시 Truist Buy
2020-07-01 개시 Cowen Outperform
2020-07-01 재확인 H.C. Wainwright Buy
2020-04-09 개시 Craig Hallum Buy
2019-12-20 개시 Oppenheimer Outperform
2019-03-05 재개 Jefferies Buy
2019-02-27 다운그레이드 Mizuho Buy → Neutral
2019-02-06 개시 Leerink Partners Outperform
2018-07-02 개시 Cantor Fitzgerald Overweight
2018-03-20 개시 Mizuho Buy
2018-02-15 개시 H.C. Wainwright Buy
2017-12-14 개시 Laidlaw Buy
2016-08-10 재확인 Jefferies Buy
2016-06-14 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2016-03-08 재확인 Stifel Buy
2015-12-17 개시 RBC Capital Mkts Outperform
2015-11-17 개시 Jefferies Buy
2015-10-30 재확인 Oppenheimer Outperform
2015-08-05 재확인 Oppenheimer Outperform
모두보기

Marinus Pharmaceuticals Inc 주식(MRNS)의 최신 뉴스

pulisher
Nov 01, 2024

Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024
pulisher
Oct 29, 2024

Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada

Oct 29, 2024
pulisher
Oct 28, 2024

Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal

Oct 28, 2024
pulisher
Oct 28, 2024

Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 27, 2024

Marinus downgraded after setback to late-stage trial - MSN

Oct 27, 2024
pulisher
Oct 26, 2024

Marinus Pharmaceuticals Hosts Investor and Analyst Day - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

TD Cowen Downgrades Marinus Pharmaceuticals (MRNS) - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

Marinus Pharmaceuticals (MRNS) Halts Ganaxolone Development for TSC After Phase 3 Trial Failure - BP Journal

Oct 26, 2024
pulisher
Oct 25, 2024

Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent - MSN

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital - TipRanks

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus stock downgraded after trial setback (MRNS:NASDAQ) - Seeking Alpha

Oct 25, 2024
pulisher
Oct 25, 2024

HC Wainwright Reiterates "Neutral" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS) - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo! Voices

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus Pharma Halts Development After Seizure Drug Fails Trial - Medical Dialogues

Oct 25, 2024
pulisher
Oct 25, 2024

JMP Securities Downgrades Marinus Pharmaceuticals (MRNS) - MSN

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus halts ganaxolone development after trial setback - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus halts ganaxolone development after trial setback By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Truist cuts Marinus Pharma to hold, drops price target - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Truist cuts Marinus Pharma to hold, drops price target By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 24, 2024

Baird cuts Marinus Pharma target to $0.50 on failed study - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options - AOL

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling - FiercePharma

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharma stock plunges to 52-week low of $0.52 - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus hits record low after discontinuing development of rare disease drug - XM

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharma stock plunges to 52-week low of $0.52 By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceutical Shares Plumb New Depths After Study Failure - MarketWatch

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Therapeutics plans layoffs, explores strategic alternatives as shares sink - The Business Journals

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharma to explore options as rare disease drug fails trial - XM

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus notes TrustTSC trial misses primary endpoint, to evaluate alternatives - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - Business Wire

Oct 24, 2024
pulisher
Oct 23, 2024

Marinus Pharmaceuticals Issues Stock Options to New Employee - MSN

Oct 23, 2024
pulisher
Oct 22, 2024

Marinus Pharmaceuticals Unveils Promising Phase 3 Trial Results for IV Ganaxolone in Treating Refractory Status Epilepticus - MSN

Oct 22, 2024
pulisher
Oct 18, 2024

Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment - Clinical Trials Arena

Oct 18, 2024
pulisher
Oct 17, 2024

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting - BioSpace

Oct 17, 2024
pulisher
Oct 17, 2024

MRNSMarinus Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan

Oct 17, 2024
pulisher
Oct 17, 2024

Marinus reports positive phase 3 seizure treatment trial results - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Marinus reports positive phase 3 seizure treatment trial results By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 15, 2024

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens - BioSpace

Oct 15, 2024
pulisher
Oct 15, 2024

Marinus Pharmaceuticals secures new US patent for epilepsy drug By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 15, 2024

Marinus Pharmaceuticals secures new US patent for epilepsy drug - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY - Business Wire

Oct 15, 2024
pulisher
Oct 15, 2024

Examining Marinus Pharmaceuticals Inc (MRNS) more closely is necessary - US Post News

Oct 15, 2024

Marinus Pharmaceuticals Inc (MRNS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Marinus Pharmaceuticals Inc 주식 (MRNS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Shafer Christina
CHIEF COMMERCIAL OFFICER
Aug 05 '24
Sale
1.14
3,820
4,355
67,406
MANNING MARTHA E
SVP, GEN. COUNSEL & CORP. SEC.
Aug 05 '24
Sale
1.13
3,621
4,092
60,263
Hulihan Joseph
CHIEF MEDICAL OFFICER
Aug 05 '24
Sale
1.13
4,828
5,456
72,725
Braunstein Scott
CHAIRMAN AND CEO
Aug 05 '24
Sale
1.13
12,145
13,724
298,667
Braunstein Scott
CHAIRMAN AND CEO
Mar 27 '24
Option Exercise
4.28
50,000
214,000
273,512
Shafer Christina
CHIEF COMMERCIAL OFFICER
Feb 20 '24
Sale
9.56
2,153
20,583
60,308
MANNING MARTHA E
SVP, GEN. COUNSEL & CORP. SEC.
Feb 20 '24
Sale
9.57
1,894
18,126
52,966
Hulihan Joseph
CHIEF MEDICAL OFFICER
Feb 16 '24
Sale
9.98
2,814
28,084
66,635
Pfanstiel Steven
CFO AND COO
Feb 16 '24
Sale
9.97
3,092
30,827
71,697
Braunstein Scott
CHAIRMAN AND CEO
Feb 16 '24
Sale
9.94
11,850
117,789
223,512
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):